OBI-1's force no longer with Inspiration and Ipsen as hemophilia asset goes over to Baxter
This article was originally published in Scrip
Executive Summary
With the sale of OBI-1 (recombinant porcine Factor VIII) to Baxter International for potentially more than $700 million and with the disposition of IB1001 (intravenous recombinant Factor IX) on the horizon, Inspiration Biopharmaceuticals has just months left before the hemophilia-focused company winds down operations after filing for Chapter 11 bankruptcy protection at the end of October (scripintelligence.com, 1 November 2012).